Oncologix Tech Stock Net Income

OCLG Stock  USD 0.0001  0.00  0.00%   
Oncologix Tech fundamentals help investors to digest information that contributes to Oncologix Tech's financial success or failures. It also enables traders to predict the movement of Oncologix Pink Sheet. The fundamental analysis module provides a way to measure Oncologix Tech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncologix Tech pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Oncologix Tech Company Net Income Analysis

Oncologix Tech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Oncologix Tech Net Income

    
  (2.37 M)  
Most of Oncologix Tech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncologix Tech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Oncologix Tech reported net income of (2.37 Million). This is 100.19% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.42% higher than that of the company.

Oncologix Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncologix Tech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oncologix Tech could also be used in its relative valuation, which is a method of valuing Oncologix Tech by comparing valuation metrics of similar companies.
Oncologix Tech is currently under evaluation in net income category among its peers.

Oncologix Fundamentals

About Oncologix Tech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Oncologix Pink Sheet

Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.